WEDNESDAY, Nov. 27, 2024 (HealthDay News) — The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of diabetes in obese prediabetic patients by more than 90% during a three-year period compared to placebo, trial resultsContinue Reading

TUESDAY, Nov. 26, 2024 (HealthDay News) — The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration.  Right now, a law passed byContinue Reading

TUESDAY, Nov. 26, 2024 (HeathDay News) — A potentially important form of brain signaling appears to be affected whenever concussion strikes, according to new research involving high school football players. “This study is important because it provides insight into both the mechanisms and the clinical implications of concussion in theContinue Reading